Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute immune toxicity during anti-thymocyte globulin: That's CARPA!
Marotta S, Ricci P, Marano L, Beneduce G, Vitagliano O, De Gregorio F, Grimaldi F, Pane F, Risitano AM. Marotta S, et al. Among authors: de gregorio f. Am J Hematol. 2018 Jan;93(1):E22-E24. doi: 10.1002/ajh.24945. Epub 2017 Nov 3. Am J Hematol. 2018. PMID: 29047151 Free article. No abstract available.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: de gregorio f. Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1. Ann Hematol. 2019. PMID: 31044260
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Mulas O, Caocci G, Stagno F, Bonifacio M, Annunziata M, Luciano L, Orlandi EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM, Cattaneo D, Attolico I, Baratè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Mulas O, et al. Among authors: de gregorio f. Ann Hematol. 2020 Jul;99(7):1525-1530. doi: 10.1007/s00277-020-04102-6. Epub 2020 May 30. Ann Hematol. 2020. PMID: 32474619
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Caocci G, Mulas O, Capodanno I, Bonifacio M, Annunziata M, Galimberti S, Luciano L, Tiribelli M, Martino B, Castagnetti F, Binotto G, Pregno P, Stagno F, Abruzzese E, Bocchia M, Gozzini A, Albano F, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, Baratè C, De Gregorio F, Stella R, Gugliotta G, Pirillo F, Trawinska MM, Sicuranza A, Cattaneo D, Attolico I, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Caocci G, et al. Among authors: de gregorio f. Ann Hematol. 2021 Aug;100(8):2005-2014. doi: 10.1007/s00277-020-04392-w. Epub 2021 Jan 3. Ann Hematol. 2021. PMID: 33388860
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Baratè C, Scaffidi L, Elena C, Giai V, Scalzulli E, Breccia M, La Nasa G, Caocci G. Mulas O, et al. Among authors: de gregorio f. Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28. Ann Hematol. 2024. PMID: 38012435 Free PMC article.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: de gregorio f. Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29633312 Free article. No abstract available.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: de gregorio f. Hematol Oncol. 2019 Aug;37(3):296-302. doi: 10.1002/hon.2606. Epub 2019 Apr 17. Hematol Oncol. 2019. PMID: 30892724 Free PMC article.
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: de gregorio f. Int J Cardiol. 2020 Feb 15;301:163-166. doi: 10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24. Int J Cardiol. 2020. PMID: 31711851
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Caocci G, Mulas O, Capodanno I, Abruzzese E, Iurlo A, Luciano L, Albano F, Annunziata M, Tiribelli M, Bonifacio M, Galimberti S, Castagnetti F, Sgherza N, Stagno F, Gozzini A, Orlandi EM, Luzi D, Binotto G, Pregno P, Fozza C, Efficace F, Simula MP, Trawinska MM, Cattaneo D, De Gregorio F, Attolico I, Stella R, Scaffidi L, Baratè C, Gugliotta G, Scalzulli E, Elena C, Pirillo F, Foà R, Breccia M, Nasa G. Caocci G, et al. Among authors: de gregorio f. Blood Cancer J. 2020 Jun 8;10(6):66. doi: 10.1038/s41408-020-0333-2. Blood Cancer J. 2020. PMID: 32514110 Free PMC article. No abstract available.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G. Mulas O, et al. Among authors: de gregorio f. Hematol Oncol. 2020 Oct;38(4):607-610. doi: 10.1002/hon.2765. Epub 2020 Jul 23. Hematol Oncol. 2020. PMID: 32602167 No abstract available.
78 results